Loading
A second HER2 antibody that binds a different spot from trastuzumab, blocking HER2 from pairing with HER3; together they extended survival by 16 months in CLEOPATRA.
Binds HER2 extracellular domain II, preventing HER2-HER3 heterodimerisation. Approved with trastuzumab and docetaxel in first-line metastatic disease (2012), neoadjuvant (2013, first pCR-based accelerated approval), and adjuvant node-positive disease (2017, APHINITY). Phesgo (2020) delivers both antibodies subcutaneously in minutes. Being partnered with T-DXd in first line (DESTINY-Breast09) and tucatinib in maintenance (HER2CLIMB-05).
Backbone ribbon from PDB 1S78. RCSB PDB 1S78. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Anti-HER2 IgG1 against subdomain II; blocks ligand-dependent HER2-HER3 signalling; ADCC. Connects to HER2 and HER3.
1.HER3, activated by neuregulin, seeks HER2 as a dimer partner
Source: www.accessdata.fda.gov/drugsatfda_docs/label/2021/125409s128lbl.pdf. Doses are for orientation; the current label governs.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Phesgo (pertuzumab + trastuzumab + hyaluronidase) is a subcutaneous clinician-administered product and also Part B.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA509 · SMC advice: pertuzumab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
First-line metastatic (CLEOPATRA)
In combination with trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early early breast cancer
Neoadjuvant accelerated approval on pCR
In combination with trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early early breast cancer
Adjuvant (APHINITY)
Phesgo SC
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer source
| Region | Year | Indication |
|---|---|---|
| US | 2012 | First-line HER2+ metastatic breast cancer with trastuzumab and docetaxel |
| US | 2013 | Neoadjuvant HER2+ early breast cancer (accelerated; first pCR-based approval) |
| US | 2017 | Adjuvant HER2+ early breast cancer at high risk of recurrence |
| US | 2020 | Phesgo subcutaneous fixed-dose combination with trastuzumab |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Diarrhoea | 67% | 8% |
| Rash | 34% | - |
| Left ventricular dysfunction | 5% | 1.2% |
| Febrile neutropenia (with docetaxel) | - | 14% |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (her2 antibodies) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
It is the proof that plasma genotyping can enrol patients for a targeted colorectal trial, which matters most for a 2 to 3% alteration where archival tissue is often exhausted or out of date.
The first prospective evidence that HER2 blockade works in biliary cancer, which led to HERIZON-BTC-01 and the HER2 antibody-drug conjugate studies; the definition of HER2-positive here (amplification or overexpression) is looser than the later IHC 3+ label.
Dual HER2 blockade after surgery is reserved for node-positive or otherwise higher-risk disease, where the benefit is real but small; node-negative patients can be spared the extra drug.
Query for this drug: (TITLE:"Pertuzumab" OR ABSTRACT:"Pertuzumab" OR TITLE:"Perjeta; Phesgo" OR ABSTRACT:"Perjeta; Phesgo" OR TITLE:"with trastuzumab" OR ABSTRACT:"with trastuzumab" OR TITLE:"subcutaneous" OR ABSTRACT:"subcutaneous") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pertuzumab, not a curated reading list.
Shares A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial, Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging, APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer, A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor.
Shares A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies, KRISTINE, HERACLES, Javier Cortés.
Shares Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009), A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer, HER2CLIMB-05, HER2 IHC 3+ (HER2-positive by immunohistochemistry).
Shares A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer, HER2 IHC 3+ (HER2-positive by immunohistochemistry), HER2-positive breast cancer with brain metastases, Early HER2-positive breast cancer.
Shares A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor, A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer, Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer, A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer.
Shares A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive , A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M, A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea, HER2.
Shares A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer, Can T-DXd alone cure early HER2-positive disease?, DESTINY-Breast09, Javier Cortés.
Shares HERACLES, HER2 ISH amplified (ERBB2 gene amplification), HER2-amplified colorectal cancer, Receptor tyrosine kinase activation.